A study published in Cell used CRISPR screening to search for new targets that could reverse age-related failure of antitumor immunity. The article reviews mechanisms by which T cell antitumor immunity declines with age, noting that older cancer patients have lower response rates to immune checkpoint inhibitors and are more prone to immune-related adverse events.
Why it matters: Age-related decline in T cell antitumor immunity underlies low ICB response rates in older patients, motivating the Cell study's CRISPR screen.
On August 13, 2026, a team led by Nicolas Thomä and Bruno Correia at EPFL (Swiss Federal Institute of Technology Lausanne) published a study titled "Proteome-wide identification of the druggable CRBN interactome" in Nature Biotechnology.
Why it matters: Reports AI mapping of the proteome-wide CRBN molecular glue binding landscape, shifting from degradation to a binding view for target discovery.
On August 12, Nature published a study from a University of California, San Francisco team. Using what is described as the world's first in vivo genome-wide CRISPR screen in human T cells, the researchers identified P2RY8-GNAS as a new target that helps CAR-T cells infiltrate and fight solid tumors more effectively.
Why it matters: In vivo genome-wide CRISPR screening in human T cells identified P2RY8-GNAS, a candidate target and screening paradigm for solid tumor CAR-T amenable to comparison with existing approaches.
A study published in Cell reports a bivalent molecular glue that bridges p300/CBP with BCL6, activating a cell death program in lymphoma cells. Using chemically induced proximity (CIP), the work targets oncogenic transcription networks that p300/CBP supports in malignant tumors by maintaining enhancer and super-enhancer activity.
Why it matters: Bridging p300/CBP with BCL6 via chemically induced proximity offers another approach to targeting enhancer-driven oncogenic transcription networks.
A Cell paper, reported by BioArt, delineates the complete mechanism of the bacterial DRT3 immune system. DRT3 contains both Class 1 and Class 2 reverse transcriptase components and synthesizes double-stranded DNA using both RNA and protein as templates to defend against phage, with protein-templated reverse transcription reported for the first time. The paper was submitted May 2, accepted July 8, and published online July 28.
Why it matters: The paper gives the mechanism by which DRT3 synthesizes double-stranded DNA from RNA and protein templates, allowing readers to compare it with known reverse-transcriptase immune systems.
Science reports the first AI-designed bacteriophage virus, capable of surviving, infecting host cells, and combating antibiotic resistance. The original article notes that previous AI designs were mostly limited to single genes or proteins, while this work achieves genome-scale design, providing a blueprint for building diverse synthetic phages and practical biological systems.
Why it matters: Notes the key advance from single-gene design to whole-genome-scale phage design, useful for assessing the boundaries of AI synthetic biology.
AbbVie has registered a Phase III trial (NCT07756645) on ClinicalTrials.gov comparing ABBV-1480 plus chemotherapy against pembrolizumab plus chemotherapy as first-line treatment in 940 patients with locally advanced or metastatic non-small cell lung cancer. ABBV-1480 (RC148) is a PD-1/VEGF bispecific antibody from RemeGen that AbbVie licensed in January for ex-Greater China rights with $650 million upfront and a $5.5 billion total deal value. The trial is expected to start in September 2026 and finish in December 2029, with PFS and OS as primary endpoints.
A Stanford University team reports in Nature that during aging, large numbers of bone marrow-derived immune cells enter the brain and convert into microglia. The finding challenges the prior view that microglia arise from embryonic settlers in the brain, self-renew throughout life, and barely interact with the peripheral immune system.
Why it matters: Stanford Nature paper shows bone marrow-derived immune cells can replenish brain microglia during aging, adding evidence on microglial origin and renewal.
A team led by Jianjun Cheng at ShanghaiTech University published a Cell paper revealing a new mechanism by which serotonin 2A receptor agonists regulate antitumor immunity in colorectal cancer. The original background notes that psychiatric symptoms such as depression and anxiety in cancer patients correlate with prognosis, and whether psychedelics have direct antitumor activity independent of central nervous system effects remains unclear. The study used the classic 5-HT2A receptor agonist lysergic acid diethylamide (LSD) as its entry point.
Why it matters: The mechanism of 5-HT2A receptor agonists in colorectal cancer antitumor immunity offers a reference for psychiatric drugs crossing into tumor immunology.
A team led by Wang Jiguang at the Hong Kong University of Science and Technology published a study online in Cell on August 3, 2026, finding ancient L1 retrotransposons upstream of many immunoglobulin heavy-chain variable region (VH) genes. B cells use the HUSH complex, normally devoted to silencing transposons, to recruit AID, making the mutation rate in VH regions 100-1000 times higher than elsewhere in the genome. In Ramos cells, the researchers inserted an ancient L1 upstream of VH4-34 and verified its function in promoting antibody diversification.
A study published in Nature Biotechnology used protein engineering to modify the botulinum neurotoxin type X protease (BoNT/X), giving it new substrate recognition capability and inducing inflammatory death in cancer cells. Conventional pyroptosis depends on caspase-1 cleavage of gasdermin D; the engineering strategy repurposes a neuron-targeting toxin for precise tumor killing.
Why it matters: The article describes engineering a botulinum toxin to induce pyroptosis in cancer cells, showing how a neurotoxin can be repurposed as a tumor-killing tool.
A UCLA team led by Thomas A. Rando reports in Science that slowed regeneration by aged muscle stem cells is not simple functional breakdown, but the result of selection favoring cells that suppress regeneration to survive long-term in the aged microenvironment. Using Pax7 promoter-driven muscle stem cell-specific NDRG1 conditional knockout mice, aged NDRG1 cKO mice showed markedly higher in vivo stem cell activation 3 days after muscle injury and significantly larger regenerating myofiber cross-sectional area at day 7, with overall regeneration speed approaching that of young mice.
Why it matters: Conditional NDRG1 knockout mice show slowed aged muscle stem cell regeneration is a survival selection outcome in the aged microenvironment, offering a new angle for aging research.
